LPCN Lipocine

Filed: 9 Jun 21, 8:01am











Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):

June 9, 2021





(Exact name of registrant as specified in its charter)


Commission File No. 001-36357 


Delaware 99-0370688
(State or other jurisdiction of incorporation) (IRS Employer Identification Number)


675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (801) 994-7383


Former name or former address, if changed since last report: Not Applicable




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareLPCNThe NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).


Emerging growth company  ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 8.01 Other Events


The Company will present data at The International Liver Congress™ 2021, the annual meeting of the European Association for the Study of the Liver (“EASL”), Digital Event, on June 23-26, 2021. The Company’s materials to be included are filed as Exhibits 99.1, 99.2 and 99.3.


Item 9.01 Financial Statements and Exhibits.


(d)       Exhibits


The following exhibits are filed with this report:


Exhibit No.Description
99.1Abstract Titled “Oral LPCN 1144 Treatment Significantly Reduced Liver Fat and Key Liver Injury Markers in Biopsy Confirmed NASH Subjects: Results of a Phase 2 Randomized Controlled Study”
99.2Abstract Titled “High Prevalence of Low Normal or Overtly Hypogonadal Levels of Testosterone Observed in Histologically Established NASH Subjects in LiFT Study”
99.3Abstract Titled “LPCN 1144 Improves Body Composition in Biopsy-Confirmed NASH Patients”









Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:June 9, 2021 By:/s/ Mahesh V. Patel
    Mahesh V. Patel
    President and Chief Executive Officer